Digitalis Ventures: Investment Portfolio & Startup News
Digitalis Ventures
To add a bio or update investment portfolio click update information.
Investment Portfolio


T-Therapeutics closes a £100m Series B led by Advent Life Sciences and British Business Bank to take its cancer and autoimmune treatments into clinical trials
T-Therapeutics is a biotechnology company developing T cell engager treatments based on human T cell receptors. Its drug programmes target cancer and autoimmune diseases.


Omni Pet secures £11m in funding led by IW Capital for veterinary-grade protein nutrition for dogs
Omni Pet is a science-led pet health company that develops calorie-controlled, novel protein foods, treats and supplements for dogs, replacing common allergens such as beef, chicken and dairy with yeast, algae and pulse-based alternatives. Founded by a practising veterinarian, the brand targets dogs with obesity, food allergies and gut sensitivities, and provides round-the-clock vet access to pet owners.


T-Therapeutics secures £24m Series A extension with Tencent and BGF to develop T cell receptor therapeutics for cancer and autoimmune disease
T-Therapeutics develops next-generation T cell receptor therapies designed to target cancer and autoimmune disease, advancing bispecific molecules that selectively remove disease-driving immune cells while preserving healthy function.
- 2(12 months)
- digitalisventures.com
More venture news
- 17 Nov 2026

Model MLModel ML secures a £190m Series B led by General Atlantic and QED Investors to expand its AI operating system for financial services
Series BFintech - 16 Nov 2026

SubdialSubdial secures a £15m Series B led by Gresham House Ventures to buy and sell pre-owned watches
Series BConsumer - 12 Nov 2026

GriffinGriffin closes a £15m Series B led by Octagon Partners to add cards and stablecoin payments to its banking platform
Series BFintech